Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017, Dana-Farber Cancer Institute
Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0

Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments. Researchers now have successfully demonstrated techniques to track these alterations over time by analyzing cell-free DNA (cfDNA) found in blood, according to Jens Lohr, MD, PhD, a hematologist and oncologist at Dana-Farber Cancer Institute.

Traditionally, progress is monitored by painful and invasive bone marrow biopsies, but those biopsies are impractical to perform repeatedly, said Lohr, who presented study results at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta.

"We asked if you could get equivalent genetic information by monitoring cell-free DNA," he said. "The short answer is yes, in principle, all this information actually is in the ."

The scientists began by performing whole genome sequencing of 110 blood samples from 75 randomly selected multiple myeloma patients for cfDNA, and used the resulting data to predict the utility of deeper whole of the cfDNA. They also obtained cfDNA, matched normal blood , and bone marrow myeloma cells from 10 myeloma patients at the same time point, and demonstrated that cfDNA whole exome sequencing robustly identified genetic mutations and these mutations matched up well with those found in sequencing bone marrow cells. The vast majority of clonal mutations and copy number variations in the bone marrow were also identified in cfDNA.

"We know that myeloma changes all the time, as evidenced by the constant relapses among patients," Lohr said. "When we follow the patient in real time, we clearly see in the blood how the genetics actually changes when the patient relapses. That means that we get very good information about the changes that happen every time drug resistance develops, which is something that is simply not practical with bone marrow biopsies."

cfDNA sequencing potentially can provide results that are more representative of myeloma throughout the body than bone marrow biopsies, which essentially represent one needle site. cfDNA analyses also should prove easier to standardize, since "it's very hard to mess up a blood " whereas marrow samples may be inconsistent, he said. Additionally, blood samples can be easily preserved and shipped for genetic tests. On the downside, however, unlike from biopsies, cfDNA cannot be enriched for myeloma-specific cfDNA. Therefore, discovery-oriented whole genome and whole exome sequencing currently are only cost-effective for active myeloma. Lohr predicts that investigations of cfDNA will be complementary with those with another form of liquid biopsy, which examines circulating tumor cells (CTCs).

"The advantage of cfDNA is that it's extremely robust, you can automate it and scale it very well, and in the near future it will be relatively easy to implement in the clinic," he said.

CTCs, in turn, allow other cell components to be analyzed in addition to DNA, such as RNA, proteins, and myeloma cell structure.

"We think both kinds of liquid biopsies add value and should be used together in clinical trials in the very near future, to try to make predictions about how drug resistance develops," he said.

Lohr cautions, however, that more research needs to be done for sequencing data from any form of biopsy to significantly aid oncologists in providing today's clinical care. One limitation is that although molecularly targeted drugs for specific genetic aberrances are in clinical trials for the disease, none is yet approved by the Food & Drug Administration.

Explore further: FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness

Related Stories

FDG PET shows tumor DNA levels in blood are linked to NSCLC aggressiveness

November 6, 2017
Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC). In a study presented in the featured clinical investigation article ...

One-size treatment for blood cancer probably doesn't fit all, researchers say

November 22, 2017
Though African-American men are three times more likely to be diagnosed with a blood cancer called multiple myeloma, most scientific research on the disease has been based on people of European descent, according to a study ...

Blood samples as surrogates for tumor biopsies in patients with lung cancer

February 26, 2015
A study examined the feasibility of using circulating free DNA (cfDNA) from blood samples of patients with advanced non-small-cell lung cancer as a surrogate for tumor biopsies to determine tumor-causing epidermal growth ...

Anti-myeloma agent opens for new treatment strategy

October 27, 2017
The tumour form multiple myeloma is very challenging to treat and is still considered incurable. In a recently published study in the scientific journal Oncotarget, researchers at Uppsala University show how inhibition of ...

New treatments to extend life for multiple myeloma patients

February 10, 2017
Multiple myeloma is a cancer of the plasma cells that reside inside bone marrow. Plasma cells produce certain proteins that build up the immune system. In abnormal quantities, these proteins damage the body and compromise ...

New method for organ transplant monitoring promises better care for patients

August 3, 2017
Using a combination of DNA sequencing and computer science techniques, a team of researchers has developed a new method for monitoring the health of organ transplant patients - one that promises to provide life-saving clues ...

Recommended for you

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.